Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle

Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration

(2011) Christian Nischler et al.   ACTA OPHTHALMOLOGICA

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

(2011) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Novel Chemosensitive Single-Nucleotide Polymorphism Markers to Targeted Regimens in Metastatic Colorectal Cancer

(2011) J. C. Kim et al.   CLINICAL CANCER RESEARCH

Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity

(2010) Milan Radovich et al.   ANGIOGENESIS

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer

(2010) J. Pander et al.   ANNALS OF ONCOLOGY

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

(2010) Marie-Christine Etienne-Grimaldi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients

(2010) F. Loupakis et al.   CURRENT CANCER DRUG TARGETS

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab

(2010) M.P. Smerdel et al.   GYNECOLOGIC ONCOLOGY

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

(2010) Gianluca Masi et al.   LANCET ONCOLOGY

Biomarkers and surrogate end points—the challenge of statistical validation

(2010) Marc Buyse et al.   Nature Reviews Clinical Oncology

6115 VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)

(2009) F. Loupakis et al.   EJC SUPPLEMENTS

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

(2009) L. Jain et al.   MOLECULAR CANCER THERAPEUTICS

Discordant somatic and germlineVEGF-Agenotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis

(2009) Luigi Coltelli et al.   PHARMACOGENOMICS

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

(2008) A. M. Schultheis et al.   CLINICAL CANCER RESEARCH

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY